Cooperative Agreement AIDGHNA000800004

The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...

This $537,672 Cooperative Agreement award from the National Center for HIV/AIDS, under the HIV Prevention Activities Health Department Based program (CFDA 93.940), supports the New York City Department of Health and Mental Hygiene's efforts to reduce tuberculosis (TB) morbidity and mortality in New York City. The key activities to be delivered include: Providing TB case management, directly observed therapy, and treatment support to all patients diagnosed with TB in New York City. 2) Identifying...

This $287,878,180 Cooperative Agreement award from the U.S. Agency for International Development (USAID) under the Foreign Assistance for Programs Overseas (CFDA 98.001) federal grant program is intended to scale up and improve management of drug-resistant tuberculosis (DR-TB) in USAID-supported countries. The award, which has an ultimate completion date of September 30, 2029, will focus on expanding access to high-quality DR-TB treatment services and providing specialized technical assistance...

This federal Cooperative Agreement award for $785,722.00 was provided by the National Center for HIV/AIDS, a civilian agency, to the Indiana Department of Health. The award supports the Indiana Tuberculosis Control Program under the Tuberculosis Elimination and Laboratory Cooperative Agreement (CFDA 93.940 - HIV Prevention Activities Health Department Based). The key products and services delivered through this funding include disease surveillance, diagnostic testing, data collection, and...

This $2,500,000 Cooperative Agreement award from the U.S. Agency for International Development (USAID) under the Foreign Assistance Program (CFDA 98.001) aims to improve the tuberculosis (TB) epidemic response in the high-burden northern and central provinces of Mozambique. The award, effective from July 12, 2024 to July 11, 2029, will be implemented by the Center for Collaboration in Health, a non-profit non-governmental organization based in Maputo, Mozambique. The project seeks to...

This $550,000 Cooperative Agreement awarded by the Centers for Disease Control and Prevention (CDC) under the Global Tuberculosis Federal Grant Program (CFDA 93.494) supports the Union Internationale Contre la Tuberculose et les Maladies Respiratoires (Uitmr), a Paris-based international non-profit organization, in collaborating to transform evidence into practice to end the tuberculosis (TB) epidemic in resource-limited countries. The five-year award period runs from September 30, 2024 to...

This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of Columbia University in the City of New York, totaling $166,541. The grant, titled "RIFAPENTINE IN HIGH DOSES IN PREGNANCY WITH TB (RADIANT-MOMS) STUDY", will be used to conduct research on optimizing tuberculosis (TB) treatment for pregnant and breastfeeding people. The key objectives of the project are to:...

This federal Cooperative Agreement award, funded by the Centers for Disease Control and Prevention (CDC) under the Project Grants and Cooperative Agreements for Tuberculosis Control Programs (CFDA 93.116), provides $210,141 to the Puerto Rico Department of Health (PRDOH) for the period of January 1, 2025 to December 31, 2029. The funding supports the Puerto Rico Tuberculosis Central Program's (PRTBCP) efforts to control and eliminate tuberculosis (TB) in Puerto Rico, which serves a population of...

This Cooperative Agreement award, funded by the Centers for Disease Control and Prevention (CDC) under the Project Grants and Cooperative Agreements for Tuberculosis Control Programs (CFDA 93.116), provides $1,420,947 to the State of Georgia Department of Public Health (GDPH) to support comprehensive tuberculosis (TB) prevention, control, and elimination efforts across the state. The key products and services to be delivered under this 5-year award (1/1/2025 - 12/31/2029) include: medical...